Thought Leader Insight & Analysis: Alzheimer's Disease - Market Research Reports

Welcome - Home - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying

| More

Hard Copy
Enterprisewide

Thought Leader Insight & Analysis: Alzheimer's Disease
Medpredict, Jan 2008



		Description



		Table of Contents


	Products Mentioned



		Enquire before Buying



		Send to a Friend

- PIB (General Electric)
- Stable Label (Bateman / Holtzman)
- 18F-AV-1/ZK (Bayer-Schering / Avid Radiopharmaceuticals)
- SA101 / SA102 (Satoris)
- Alzhemed (tramiprosate; NC758; Neurochem)
- Xaprila (xaliproden; Sanofi-Aventis)
- Aricept (donepezil; Eisai / Pfizer)
- Exelon (rivastigmine; Novartis)
- Razadyne ER (galantamine; J&J)
- Debio 9902 SR (Debio)
- NGX267 (TorreyPines)
- Namenda / Axura / Ebixa (memantine; Forest / Merz / Lundbeck / Daiichi-Sankyo)
- Dimebon (dimebolin; Medivation)
- MK-0249 (Merck)
- 742457 (SB-742457; GSK)
- NP-0361 (Neuropharma / Zeltia)
- ABT-089 (Abbott)
- AZD-0328 (AstraZeneca)
- R-4996 / MEM-63908 (Roche / Memory)
- EVP-6124 (EnVivo / Bayer-Schering)
- Gammagard (IVIG; Baxter)
- bapineuzumab (AAB-001; Elan/Wyeth)
- LY2062430 (Lilly)
- PF-4360365 (RN1219; Pfizer)
- AAB-002 (Elan / Wyeth)
- ACU-5A5 Mab (Merck)
- BAN-2401 (Eisai / BioArctic)
- R-1450 (Roche / Morphosys)
- ACI-01-Ab7 (AC Immune / Genentech)
- Affitope AD01 (Affiris)
- CAD-106 (Novartis)
- V-950 (Merck)
- ACC-001 (Elan / Wyeth)
- ACI-24 (AC Immune)
- Boehringer-Ingelheim / Ablynx
- PADRE (Lundbeck / Pharmexa)
- Flurizan (tarenflurbil; R-flurbiprofen; Myriad)
- LY-450139 (Lilly / Elan)
- MK-0752 (Merck)
- GSI-953 (Wyeth)
- ?-secretase (Schering-Plough Elan BMS TorreyPines Cellzome / J&J)
- CTS-21166 (CoMentis)
- BACE (Lilly Sunesis/Merck GSK BMS Astex/AstraZeneca Amgen)
- Enbrel (etanercept; Wyeth/Amgen)
- Avandia (rosiglitazone; GSK)
- TTP-488 (RAGE Inhibitor; TransTec / Pfizer)
- NGX-96992 (TorreyPines)
- Insulin Degrading Enzyme (Wyeth) Ketasyn (AC-1202; Accera)
- SRT-501; NCE-1; NCE-2 (Sirtris)
- NP031112 (Neuropharma)
- GSK-3 (AstraZeneca)
- PAI-1 Antagonist (Wyeth)
- PBT2 (Prana)
- Lipitor (atorvastatin; Pfizer)
- Zocor (simvastatin; Merck)
- Evista (raloxifene; Lilly)
- lecozotan (Wyeth)
- PRX-03140 (Epix / GSK)
- ELND005 (scyllo-inositol; AZD-103; Elan / Transition Therapeutics)
- MK-0249 (Merck)

Customers who bought this item also bought

Wyeth

Alzheimer Disease - New Drugs, Markets and Companies

Central Nervous System Alzheimer Disease

Analysis of Wyeth

Central Nervous System - Alzheimer Disease Drug Pipeline Report

Emerging Drug Targets in Alzheimer's Disease

Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript

Bapineuzumab Phase 2 Clinical Trial Results Call - Wyeth,Elan Corp. Plc, - Earnings Transcript

Small Molecule Kinase Inhibitors - Global Strategic Business Report

CNS Drug Discoveries: Alzheimer's Disease Chapter

Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript

Acquisition of Wyeth by Pfizer, Inc Call - - Earnings Transcript

Top of page